These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 15019558)

  • 21. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland.
    Inoue T; Domae M; Yamada K; Furukawa T
    J Pharmacol Exp Ther; 1996 Apr; 277(1):137-43. PubMed ID: 8613910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Geissoschizine methyl ether has third-generation antipsychotic-like actions at the dopamine and serotonin receptors.
    Ueda T; Ugawa S; Ishida Y; Shimada S
    Eur J Pharmacol; 2011 Dec; 671(1-3):79-86. PubMed ID: 21951966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
    Natesan S; Reckless GE; Nobrega JN; Fletcher PJ; Kapur S
    Neuropsychopharmacology; 2006 Sep; 31(9):1854-63. PubMed ID: 16319908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
    Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine D2(High) receptors moderately elevated by bifeprunox and aripiprazole.
    Seeman P
    Synapse; 2008 Dec; 62(12):902-8. PubMed ID: 18792990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medications for stimulant abuse: agonist-based strategies and preclinical evaluation of the mixed-action D-sub-2 partial agonist aripiprazole (Abilify).
    Bergman J
    Exp Clin Psychopharmacol; 2008 Dec; 16(6):475-83. PubMed ID: 19086768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aripiprazole and haloperidol suppress excessive dopamine release in the amygdala in response to conditioned fear stress, but show contrasting effects on basal dopamine release in methamphetamine-sensitized rats.
    Oshibuchi H; Inada K; Sugawara H; Ishigooka J
    Eur J Pharmacol; 2009 Aug; 615(1-3):83-90. PubMed ID: 19477171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels.
    Heusler P; Newman-Tancredi A; Castro-Fernandez A; Cussac D
    Neuropharmacology; 2007 Mar; 52(4):1106-13. PubMed ID: 17239906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
    Rugsley TA; Davis MD; Akunne HC; Cooke LW; Whetzel SZ; MacKenzie RG; Shih YH; van Leeuwen DH; DeMattos SB; Georgic LM
    J Pharmacol Exp Ther; 1995 Aug; 274(2):898-911. PubMed ID: 7636753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice.
    Leite JV; Guimarães FS; Moreira FA
    Eur J Pharmacol; 2008 Jan; 578(2-3):222-7. PubMed ID: 18021764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
    Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G
    J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The agonist activities of the putative antipsychotic agents, L-745,870 and U-101958 in HEK293 cells expressing the human dopamine D4.4 receptor.
    Gazi L; Bobirnac I; Danzeisen M; Schüpbach E; Bruinvels AT; Geisse S; Sommer B; Hoyer D; Tricklebank M; Schoeffter P
    Br J Pharmacol; 1998 Jul; 124(5):889-96. PubMed ID: 9692773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain.
    Li Z; Ichikawa J; Dai J; Meltzer HY
    Eur J Pharmacol; 2004 Jun; 493(1-3):75-83. PubMed ID: 15189766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.
    Shapiro DA; Renock S; Arrington E; Chiodo LA; Liu LX; Sibley DR; Roth BL; Mailman R
    Neuropsychopharmacology; 2003 Aug; 28(8):1400-11. PubMed ID: 12784105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aripiprazole acts as a selective dopamine D2 receptor partial agonist.
    Wood M; Reavill C
    Expert Opin Investig Drugs; 2007 Jun; 16(6):771-5. PubMed ID: 17501690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inverse agonism at dopamine D2 receptors. Haloperidol-induced prolactin release from GH4C1 cells transfected with the human D2 receptor is antagonized by R(-)-n-propylnorapomorphine, raclopride, and phenoxybenzamine.
    Nilsson CL; Ekman A; Hellstrand M; Eriksson E
    Neuropsychopharmacology; 1996 Jul; 15(1):53-61. PubMed ID: 8797192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
    Heusler P; Newman-Tancredi A; Loock T; Cussac D
    Eur J Pharmacol; 2008 Feb; 581(1-2):37-46. PubMed ID: 18190908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.
    Keck PE; McElroy SL
    Expert Opin Investig Drugs; 2003 Apr; 12(4):655-62. PubMed ID: 12665420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperprolactinemia with aripiprazole: understanding the paradox.
    Saraf G; Behere RV; Venkatasubramanian G; Rao NP; Varambally S; Gangadhar BN
    Am J Ther; 2014; 21(3):e80-1. PubMed ID: 22357167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The antipsychotic aripiprazole antagonizes the ethanol- and amphetamine-induced locomotor stimulation in mice.
    Jerlhag E
    Alcohol; 2008 Mar; 42(2):123-7. PubMed ID: 18358991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.